Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
Abstract Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched,...
Guardado en:
Autores principales: | Gaia Griguolo, Maria Vittoria Dieci, Laia Paré, Federica Miglietta, Daniele Giulio Generali, Antonio Frassoldati, Luigi Cavanna, Giancarlo Bisagni, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Guido Ficarra, Aleix Prat, Pierfranco Conte, Valentina Guarneri |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3153978b88de488eab2304b48b93ed3a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Federica Miglietta, et al.
Publicado: (2021) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Fara Brasó-Maristany, et al.
Publicado: (2020) -
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Maria Vittoria Dieci, et al.
Publicado: (2021) -
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: G. Griguolo, et al.
Publicado: (2021) -
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
por: Leticia De Mattos-Arruda, et al.
Publicado: (2021)